Shimomura M, Ashiarai M, Kato I, Kamiya T, Taketomi N, Akita T
Int J Hematol. 2025; .
PMID: 40063330
DOI: 10.1007/s12185-025-03961-x.
Leimi L, Vettenranta K, Meri S
Sci Rep. 2025; 15(1):7073.
PMID: 40016347
PMC: 11868490.
DOI: 10.1038/s41598-025-91455-5.
Uysal A, Soyer N, Ozdogu H, Goker H, Cinar O, Deveci B
Indian J Hematol Blood Transfus. 2025; 41(1):43-52.
PMID: 39917483
PMC: 11794778.
DOI: 10.1007/s12288-024-01800-3.
Ursu S, Alhousani M, Patrus G, Fazal S
Cureus. 2025; 16(12):e75270.
PMID: 39776713
PMC: 11703650.
DOI: 10.7759/cureus.75270.
Zhu X, Wang J, Fu H, Han T, Xu Z, Zhang X
Zhonghua Xue Ye Xue Za Zhi. 2025; 45(12):1078-1084.
PMID: 39765347
PMC: 11886692.
DOI: 10.3760/cma.j.cn121090-20240701-00240.
Comparative retrospective analysis of cord blood transplantation with ATG-containing conditioning regimens and haploidentical stem cell transplantation: similar survival outcomes with reduced incidence of GVHD.
Liu Y, Liang Z, Ren H, Dong Y, Liu W, Yin Y
Ann Med. 2025; 57(1):2447402.
PMID: 39749649
PMC: 11703471.
DOI: 10.1080/07853890.2024.2447402.
F-FLT PET and Blood-based Biomarkers for Identifying Gastrointestinal Graft versus Host Disease after Allogeneic Cell Transplantation.
Holter-Chakrabarty J, McNally L, Levine J, Ferrara J, Vesely S, Kanakry C
Radiol Imaging Cancer. 2024; 7(1):e240096.
PMID: 39670843
PMC: 11791676.
DOI: 10.1148/rycan.240096.
Time-restricted versus standard-duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON-96 trial.
Broers A, Meijer E, van der Holt B, de Jong C, Nur E, van Sluis G
Hemasphere. 2024; 8(12):e70040.
PMID: 39665067
PMC: 11632395.
DOI: 10.1002/hem3.70040.
The EASIX score as a predictor of sinusoidal obstruction syndrome and nonrelapse mortality in paediatric patients receiving allogeneic haematopoietic stem cell transplantation.
Muratore E, Gambuti G, Leardini D, Baccelli F, Venturelli F, Larcinese L
Bone Marrow Transplant. 2024; 60(3):346-352.
PMID: 39658654
PMC: 11893459.
DOI: 10.1038/s41409-024-02489-8.
Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM.
Kalwak K, Moser L, Potschger U, Bader P, Kleinschmidt K, Meisel R
Blood Adv. 2024; 9(4):741-751.
PMID: 39602342
PMC: 11869852.
DOI: 10.1182/bloodadvances.2024014548.
Evaluation of the Clinical Outcomes of Cyclosporine Short Infusion Versus Continuous Infusion Postallogenic Stem Cell Transplantation.
El-Awady S, El Afifi A, Afifi R, Sabri N, Ahmed M
Eur J Drug Metab Pharmacokinet. 2024; 50(1):53-64.
PMID: 39601981
DOI: 10.1007/s13318-024-00927-y.
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
Kiene S, Albrecht M, Theurich S, Scheid C, Skoetz N, Holtick U
Cochrane Database Syst Rev. 2024; 11:CD010189.
PMID: 39508306
PMC: 11542152.
DOI: 10.1002/14651858.CD010189.pub3.
Safety and Efficacy of Extracorporeal Photopheresis for Acute and Chronic Graft-versus-Host Disease.
Gavriilaki E, Papchianou E, Karavalakis G, Batsis I, Panteliadou A, Lazaridou A
Pharmaceuticals (Basel). 2024; 17(10).
PMID: 39458920
PMC: 11510389.
DOI: 10.3390/ph17101279.
A comparison of haploidentical versus HLA-identical sibling outpatient hematopoietic cell transplantation using reduced intensity conditioning in patients with acute leukemia.
Jaime-Perez J, Valdespino-Valdes J, Gomez-De Leon A, Barragan-Longoria R, Dominguez-Villanueva A, Cantu-Rodriguez O
Front Immunol. 2024; 15:1400610.
PMID: 39430740
PMC: 11486716.
DOI: 10.3389/fimmu.2024.1400610.
Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD.
Olivieri A, Mancini G
Cells. 2024; 13(18.
PMID: 39329708
PMC: 11431085.
DOI: 10.3390/cells13181524.
Dietary intake and risk of metabolic syndrome in long-term survivors of pediatric allogeneic hematopoietic stem cell transplantation.
Pedersen L, Gerbek T, Sorum M, Muhic E, Christiansen T, Kok K
Bone Marrow Transplant. 2024; 59(12):1710-1716.
PMID: 39294427
PMC: 11611737.
DOI: 10.1038/s41409-024-02412-1.
Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease.
Zu Y, Gui R, Li Z, Wang J, Li P, Liu Y
Ther Adv Hematol. 2024; 15:20406207241276982.
PMID: 39247427
PMC: 11380122.
DOI: 10.1177/20406207241276982.
Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk, first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen.
Peters C, Bruno A, Rizzari C, Brescianini A, von Stackelberg A, Linderkamp C
Haematologica. 2024; 110(1):234-238.
PMID: 39234873
PMC: 11694122.
DOI: 10.3324/haematol.2024.285837.
In vitro assessment of nanomedicines' propensity to cause palmar-plantar erythrodysesthesia: A Doxil vs. doxorubicin case study.
Cedrone E, Ishaq A, Grabarnik E, Edmondson E, Skoczen S, Neun B
Nanomedicine. 2024; 62:102780.
PMID: 39181221
PMC: 11513236.
DOI: 10.1016/j.nano.2024.102780.
Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation.
Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Diaz-Fernandez P
Nat Biotechnol. 2024; .
PMID: 39169264
DOI: 10.1038/s41587-024-02348-3.
